Protara Therapeutics Secures $75M Funding Round To Accelerate TARA-002 Development And Broader Clinical Programs

New_Ser_Ngmi · 2025-12-26T02:38:53+00:00

Protara Therapeutics plans to raise $75 million through a public offering of 13 million shares at $5.75 each, focusing on advancing its investigational therapies, particularly TARA-002 for pediatric lymphatic malformations. Despite an 18% share decline post-announcement, proceeds will finance clinical initiatives and corporate operations.

New_Ser_Ngmi

2025-12-26 02:38:53

Abstract generation in progress

Protara Therapeutics Inc. (TARA) has unveiled plans to raise $75 million through an underwritten public offering, issuing 13 million shares at $5.75 per share. The capital infusion underscores the company’s commitment to advancing its pipeline of investigational cell therapies, with TARA-002 positioned as the primary focus.

Funding Details And Market Response

The offering, expected to close around December 8, 2025, grants underwriters a 30-day option to purchase an additional 1.95 million shares at the same price. Following the announcement, TARA shares declined over 18% to $5.55 in premarket trading Friday, a notable shift from Thursday’s close of $6.87. Despite the immediate pullback, investors have historically valued the stock between $2.77 and $7.82 over the past year.

Strategic Use Of Capital

Protara will deploy proceeds to fund the broader clinical initiatives within its portfolio. The lead indication remains TARA-002, an investigational cell therapy derived from Streptococcus pyrogenes, currently advancing through Phase 2 open-label trials for pediatric lymphatic malformations (LMs). The same therapy is being evaluated for non-muscle invasive bladder cancer (NMIBC) applications.

TARA-002 carries significant regulatory tailwinds: the FDA has granted Rare Pediatric Disease designation, while the European Commission awarded Orphan Drug status for lymphatic malformations. Beyond TARA-002, the company is pushing forward with IV Choline Chloride for patients requiring parenteral support, which has secured both Orphan Drug and Fast Track designations from the FDA.

The $75 million raise provides the financial runway needed to support these clinical objectives while funding broader corporate operations and working capital requirements.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.